Skip to main content

Share story

AI

OpenAI seeks approximately $30 billion in accelerated funding round

OpenAI seeks approximately $30 billion in accelerated funding round Image: Primary
OpenAI is seeking approximately $30 billion in funding that could push its valuation over $1.4 trillion, note reported, citing Reuters reporting from October 19. The company aims to secure investor commitments before mid-November, when rival Anthropic is expected to go public. Existing investors considering participation include SoftBank Group and MGX. OpenAI has been meeting long-only funds and sovereign wealth funds as the two AI companies compete for investors. The fundraising would support infrastructure investments, including data centers, and provide a financial buffer if a cooling IPO market delays OpenAI's planned 2027 public offering. The round's closing date and final valuation remain unconfirmed.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from note and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Infrastructure
AI Infrastructure

Nvidia opens access to BSC AI Factory services through Inception portal

Some Barcelona Supercomputing Center AI Factory services are now accessible through Nvidia's Inception portal, Nvidia announced. BSC's AI Factory Accelerator Programme has also moved from a pilot into full operation, giving startu...

Products
Products

FNZ directors to face staff shareholders in dilution dispute

Directors of digital wealth management platform FNZ Group Ltd. will face staff shareholders in open court in New Zealand over claims that their stakes were unfairly diluted. FNZ is backed by some of the world's largest institution...

Security AI
Security AI

Security firm links AI tool to corporate breaches in Japan

Hackers who recently infiltrated some of Japan's biggest companies used an AI tool developed in China, according to a Tokyo-based internet security firm. The firm linked the same tool to a rash of breaches at South Korean banks la...

Science
Science

Ocugen changes primary measure in Phase 3 OCU400 trial

Ocugen has changed the primary outcome measure for its pivotal Phase 3 OCU400 gene therapy trial from MLMT to LDNA, newscase reported, citing an investor presentation carried in an SEC filing. The company confirmed enrollment of 1...